Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $25.85 in the prior trading day, Zenas Biopharma Inc (NASDAQ: ZBIO) closed at $26.99, up 4.41%. In other words, the price has increased by $4.41 from its previous closing price. On the day, 0.52 million shares were traded. ZBIO stock price reached its highest trading level at $27.13 during the session, while it also had its lowest trading level at $25.88.
Ratios:
Our goal is to gain a better understanding of ZBIO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wedbush on March 20, 2025, initiated with a Outperform rating and assigned the stock a target price of $35.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $19.
On December 16, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.H.C. Wainwright initiated its Buy rating on December 16, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 09 ’25 when Nunn Jason Raleigh bought 63,158 shares for $19.00 per share. The transaction valued at 1,200,002 led to the insider holds 1,173,395 shares of the business.
SR ONE CAPITAL MANAGEMENT, LLC bought 126,315 shares of ZBIO for $2,399,985 on Oct 09 ’25. The 10% Owner now owns 1,917,895 shares after completing the transaction at $19.00 per share. On Oct 09 ’25, another insider, ENRIGHT PATRICK G, who serves as the Director of the company, bought 105,265 shares for $19.00 each. As a result, the insider paid 2,000,035 and bolstered with 1,832,669 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBIO now has a Market Capitalization of 1271507328 and an Enterprise Value of 864286336. For the stock, the TTM Price-to-Sale (P/S) ratio is 75.77 while its Price-to-Book (P/B) ratio in mrq is 4.74. Its current Enterprise Value per Revenue stands at 57.619 whereas that against EBITDA is -4.573.
Stock Price History:
The Beta on a monthly basis for ZBIO is -1.76, which has changed by 0.2045666 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, ZBIO has reached a high of $29.73, while it has fallen to a 52-week low of $5.83. The 50-Day Moving Average of the stock is 38.61%, while the 200-Day Moving Average is calculated to be 123.94%.
Shares Statistics:
The stock has traded on average 244.36K shares per day over the past 3-months and 437340 shares per day over the last 10 days, according to various share statistics. A total of 42.09M shares are outstanding, with a floating share count of 10.27M. Insiders hold about 75.60% of the company’s shares, while institutions hold 37.28% stake in the company. Shares short for ZBIO as of 1759190400 were 5616578 with a Short Ratio of 22.98, compared to 1756425600 on 5760485. Therefore, it implies a Short% of Shares Outstanding of 5616578 and a Short% of Float of 19.569999.
Earnings Estimates
. The current rating of Zenas Biopharma Inc (ZBIO) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.92, with high estimates of -$0.64 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$2.56 and -$4.47 for the fiscal current year, implying an average EPS of -$3.52. EPS for the following year is -$5.18, with 2.0 analysts recommending between -$4.76 and -$5.61.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for ZBIO’s current fiscal year. The highest revenue estimate was $90M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $35.83M. In the same quarter a year ago, actual revenue was $5M
